Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 10 Feb 2017
At a glance
- Drugs Sunitinib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms SURTIME
- 07 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 May 2017.
- 11 Jul 2016 Planned End Date changed from 1 Oct 2014 to 1 Dec 2016.
- 11 Jul 2016 Status changed from recruiting to active, no longer recruiting.